ロード中...
Efficacy and safety of extimia® (empegfilgrastim): results of a double-blind controlled phase iii study in patients with diagnosis «breast cancer» receiving myelosuppressive chemotherapy
Objectives: to compare safety and efficacy of a single dose of empegfilgrastim and daily dosing of filgrastim for prevention of neutropenia in patients receiving AT (docetaxel 75 mg/m2 + doxorubicin 50 mg/m2). Methods. 135 patients with breast cancer were randomly assigned at a ratio of 1:1:1 to rec...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Russo |
| 出版事項: |
IP Habib O.N.
2015-06-01
|
| シリーズ: | Современная онкология |
| 主題: | |
| オンライン･アクセス: | https://modernonco.orscience.ru/1815-1434/article/view/27010 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|